Susceptibility-based MRI biomarkers, including paramagnetic rim lesions (PRLs) and central vein sign (CVS), were incorporated into the 2024 McDonald criteria because they improve diagnostic specificity in adult-onset MS; however, their role in pediatric-onset MS (POMS) remains incompletely defined. To synthesize curren...
Anna de Mauro, Rosa Cortese, Giulia Fadda et al.· Journal of Neurology· 0 citations
Key Points Question What is the long-term safety and efficacy profile of ocrelizumab in patients with relapsing multiple sclerosis (RMS)? Findings In the OPERA I/II randomized clinical trials including 1656 patients with RMS, treatment with ocrelizumab for up to 10 years led to near-complete and sustained suppression o...
Stephen L. Hauser, Amit Bar-Or, G. Giovannoni et al.· JAMA Neurology· 0 citations
It is suggested that serum GFAP may serve as a biomarker for personalized risk stratification and treatment monitoring and as a screening tool to reduce cohort size in clinical trials targeting MS progression.
M. Einsiedler, S. Sandgren, S. Schaedelin et al.· JAMA Neurology· 0 citations
CP volume was increased in both active RMS and inactive PMS and was associated with lower total and cortical brain volumes, suggesting CP volume may reflect processes beyond MS-specific pathology, including physiological factors.
M. Mastantuono, A. Cagol, M. Ocampo-Pineda et al.· Multiple Sclerosis· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
